Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

• Status: COMPLETED
• Trial end date: 2025-03-19

Summary

This is Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria

• Phase: PHASE2

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Artemether, Lumefantrine Drug Combination; ganaplacide; NITD 609